Company attributes
B2X
0
Pitchbook URL
Number of Employees (Ranges)
1 – 100
Full Address
Nihonbashi Life Science Building 2, 504
3-11-5 Nihonbashi-Honcho, Chuo-ku
Tokyo, 103-0023
Japan
Founded Date
2017
Venture Capital Firm attributes
Other attributes
Company Operating Status
Closed
Axil Capital is a venture capital and private equity firm investing in early-stage biomedical & healthcare technology companies that is headquartered in Tokyo, Japan and was founded in 2017 by Fred Shane and Hiroshi Gonaikawa. Axil Capital was spun out of Mizuho Securities in 2017 after receiving investment from the Japanese Government, a global pharmaceutical company, and a few small investors.
Notable investments made by Axil Capital include: Jolly Good! (sereis B-II), Frequency Therapeutics (series B and series C), United Immunity (series A), TechsoMed (series A).
Investment funds
According to the firms website (as of November 2019), Axil Capital has one investment fund called the Axil Life Science & Healthcare Fund No.1 L.P. (ALHF I).
Timeline
No Timeline data yet.
Associated Investment Funds
Accelerator Batches
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Funding Rounds Participated In
Further Resources
No Further Resources data yet.
